Sponsors

Lead Sponsor

Amgen

Collaborators

Parexel

Approximately 170 subjects will be randomized 1:1 in approximately 40 sites in China. This study consists of a screening period of up to 28 days, followed by a treatment period of 18 weeks, and an end of study visit 3 weeks after the last dose of investigational product or study-specified chemotherapy. After randomization, subjects will receive investigational product at a dose of 15 mg/kg administered every 3 weeks for 6 cycles followed by at least 4 and no more than 6 cycles of carboplatin and paclitaxel chemotherapy every 3 weeks.

Related studies

RECRUITINGPhase 3

First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

NCT06840782 · Oligometastatic Non-small Cell Lung Cancer (NSCLC)

RECRUITING

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

NCT02622581 · Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic, and more

Active Not RecruitingPhase 2

Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

NCT05751187 · Non-squamous NSCLC

Active Not RecruitingPhase 4

AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC

NCT04413201 · Non-squamous NSCLC

COMPLETEDPhase 3

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

NCT04447118 · Non-squamous NSCLC, HER2 Exon 20 Mutation

View all related studies →

A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

What this study is about

Clareo turns complex medical information into clear understanding you can use.